Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma ; volume:14 ; number:1 ; day:31 ; month:5 ; year:2024 ; pages:1-8 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (31.5.2024), 1-8, 12.2024

Creator
Nath, Karthik
Shekarkhand, Tala
Nemirovsky, David
Derkach, Andriy
Costa, Bruno Almeida
Nishimura, Noriko
Farzana, Tasmin
Rueda, Colin
Chung, David J.
Landau, Heather J.
Lahoud, Oscar B.
Scordo, Michael
Shah, Gunjan L.
Hassoun, Hani
Maclachlan, Kylee
Korde, Neha
Shah, Urvi A.
Tan, Carlyn Rose
Hultcrantz, Malin
Giralt, Sergio
Usmani, Saad Z.
Shahid, Zainab
Mailankody, Sham
Lesokhin, Alexander M.
Contributor
SpringerLink (Online service)

DOI
10.1038/s41408-024-01043-5
URN
urn:nbn:de:101:1-2409252059501.664559478449
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nath, Karthik
  • Shekarkhand, Tala
  • Nemirovsky, David
  • Derkach, Andriy
  • Costa, Bruno Almeida
  • Nishimura, Noriko
  • Farzana, Tasmin
  • Rueda, Colin
  • Chung, David J.
  • Landau, Heather J.
  • Lahoud, Oscar B.
  • Scordo, Michael
  • Shah, Gunjan L.
  • Hassoun, Hani
  • Maclachlan, Kylee
  • Korde, Neha
  • Shah, Urvi A.
  • Tan, Carlyn Rose
  • Hultcrantz, Malin
  • Giralt, Sergio
  • Usmani, Saad Z.
  • Shahid, Zainab
  • Mailankody, Sham
  • Lesokhin, Alexander M.
  • SpringerLink (Online service)

Other Objects (12)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia

Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia

New therapies in multiple myeloma

New therapies in multiple myeloma

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

Estrogenic or antiestrogenic therapies for multiple myeloma?

Estrogenic or antiestrogenic therapies for multiple myeloma?

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Development of Antibody‐Directed Therapies: Quo Vadis?

Development of Antibody‐Directed Therapies: Quo Vadis?

Pathogenesis and current therapies for non-infectious uveitis

Pathogenesis and current therapies for non-infectious uveitis

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

CAR T therapies in multiple myeloma: unleashing the future

CAR T therapies in multiple myeloma: unleashing the future

Related objects